Our website does not fully support your browser.

We've detected that you are using an older version of Internet Explorer. Your commerce experience may be limited. Please update your browser to Internet Explorer 11 or above.

Limited Functionality Warning

We are currently updating our network. During this time, certain functionality may be unavailable, including online orders. We apologize for any inconvenience this may cause you.

Please contact Customer Service with any questions or comments.
Phone: (608) 274-4330
Toll-Free Phone: (800) 356-9526
Email: custserv@promega.com
Hours: 7am – 6pm, CST, Monday-Friday

We believe this site might serve you best:

United States

United States

Language: English

Promega's Cookie Policy

Our website uses functional cookies that do not collect any personal information or track your browsing activity. When you select your country, you agree that we can place these functional cookies on your device.

Bright-Glo™ Luciferase Assay System Technical Manual

Instructions for Use of Product(s)
E2610, E2620, E2650

Literature # TM052

Ultrahigh-throughput quantitation of luciferase expression in mammalian cells requires highly sensitive reagents that can adapt to continuous process robotic systems. The Bright-Glo™ Luciferase Assay System is designed specifically to meet the needs of continuous process systems by providing a homogeneous assay chemistry that achieves high sensitivity and approximately half-hour signal half-life without prior sample processing. These attributes also benefit scientists using fewer samples who still require high sensitivity and ease of use.
The Bright-Glo™ Luciferase Assay System is designed for use with the following culture media containing 0–10% serum: RPMI 1640, MEM-alpha,DMEM and Ham’s F12. The signal half-life under these conditions will generally exceed 25 minutes at 22°C and is independent of enzyme concentration where the luciferase concentration is <10–9M. Other media/sera combinations also can be used, but experimental verification of assay performance is recommended in these cases.

Summary of Changes, 9/15 Revision
The following changes were made to the 9/15 version of this document:
Expired patent information was removed.

Printed in USA. Revised 9/15.

Experienced User Protocols